Modern approaches to the treatment of type 2 diabetes mellitus and its complications

Close metadata

Recommended articles:

Causes of hospital mortality in adults based on medical certificates of death. Russian Journal of Preventive Medicine. 2024;(3):7-13

Optimizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77

Modern issues of lung tuberculosis and diabetes mellitus on the tobacco consumption background in the world and the Russian Federation. Russian Journal of Preventive Medicine. 2024;(4):97-102

Outcomes of bimanual vitreoretinal surgery in the treatment of diabetic retinopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27

Impact of SGLT2 inhibitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chronic heart failure. Russian Journal of Preventive Medicine. 2024;(5):103-110

Incidence of carbohydrate metabolism disorder in iron overload of different etiology. Russian Journal of Preventive Medicine. 2024;(5):111-117

Fatal case of rhinocerebral mucormycosis on the background of type II diabetes mellitus. Russian Journal of Archive of Pathology. 2024;(3):52-58

Endarterectomy from superficial femoral artery in patients with type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):285-293

Evaluation of revascularization efficiency using near-infrared oximetry in patients with diabetic foot syndrome. Pirogov Russian Journal of Surgery. 2024;(6):20-27

Features of the oral microbiota in patients with type II diabetes in the background of dental implantation. Russian Journal of Stomatology. 2024;(2):21-26

According to the International Diabetes Federation, there are over 366 mln subjects suffering diabetes mellitus (DM) in the world. This figure is expected to reach 552 mln by 2030. The patients are treated with preparations acting on different components of DM pathogenesis on the one hand and with medicines facilitating prophylaxis of the disease on the other hand. Diabeton MB decreases the mean HbA1c level of 7-8% by 0.9%. Also, it causes reduction of the initial HbA1c levels of 8-9% and 10% by 1.7% (2.6---??) and 4.2% respectively. Diabeton MB produces a number of other effects besides the hypoglycemic activity; specifically, it reduces the intensity of LDLP oxydation, platelet adhesion and aggregation, adhesion of monocytes, etc.

Keywords:

diabetes mellitus

insulin therapy

NPH

insulin glargine

ORIGIN

Authors:

Ametov A.S.

Federal'noe agentstvo po zdravookhraneniiu i sotsial'nomu razvitiiu;
GOU DPO Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Doskina E.V.

GBOU DPO RMAPO, Moskva

List of references:

Butler P.C., Meier J.J., Butler A.E., Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758-768.
Ametov A.S. Narusheniya zhiznennogo tsikla i funktsii Β-kletok podzheludochnoi zhelezy: tsentral'noe zveno patogeneza cakharnogo diabeta 2-go tipa. Uchebnoe posobie. M 2002.
Barr R.G., Nathan D.M., Meigs J.B., Singer D.E. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Int Med 2002; 137: 4: 263-272.
UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
Riddle M. et al. Shallenging the "Monnier concept": High basal (not postpandial) glucose dominates hyperglycaemic exposure over a wide range of HbA1c in oral therapy and contributes significantly even after addition of basal insulin. Diabetologia 2010; 53: Suppl 1: Abstart 999.
Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi. 5-e izd. M 2011.et al.
Gaede P.S. et al. Effect of multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008; 258: 580-591.
Ramlo-Halsted B.A., Edelman S.V. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care 1999; 26: 4: 771-789.
De Fronzo R.A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50: 5: 191-197.
Gerstein H.C., Yale J.-F., Harris S.B., Issa M., Stewart J.A., Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-742.
Blicklé J.F., Hancu N., Piletic M., Profozic V., Shestakova M., Dain M.P., Jacqueminet S., Grimaldi A. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009; 11: 4: 379-386.
Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
Chang-Yu Pan et al. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabet Res Clin Pract 2007; 76: 111-118.
Riddle M.C. et al. The Treat-to-Target Trial. Diabetes Care 2003; 26: 3080-3086.
Rosenstock J., Schwarts S.L., Clark C.M.Jr., Park G.D., Donley D.W., Edwards M.B. Diabetes Care 2001; 24: 631-636.
Yki-Jarvinen H., Dressler A., Ziemen M. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 8: 1130-1136.
Davies M., Evans R., Storms F. et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes. Comparison of two treatment algorithms using insulin glargine . Diabetes Care 2005; 28: 1282-1288.
Yarek-Martynova I.R., Shamkhalova M.Sh., Shestakova M.V. Effektivnaya farmakoterapiya v endokrinologii. M 2010; 6: 24-28.
Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vahatalo M., Virtamo H., Nikkila K., Tulokas T., Hulme S., Hardy K.,McNulty S., Hanninen J., Levanen H., Lahdenpera S., Lehtonen R., Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 3: 442-451.
Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on.oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 1: 31-38.
Schreiber S.A., Ferlinz K., Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008; 10: 2: 121-127.
The ORIGIN Trial Investigators Hamilton, Ontario, Canada. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26-32: e6.
The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. The New England Journal of Medicine. 2012, NEJM.org
Nathan D.M., Busse J.B., Davidson M.B. Medical management of hyperglycemia in type 2 diabetes: aa consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabet Care 2009; 32: 193-203.

Close metadata